{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T01:36:53Z","timestamp":1774661813843,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.repc.2025.11.007","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T17:05:45Z","timestamp":1769533545000},"page":"135-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Costs and consequences of cardiovascular toxicity due to Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"45","author":[{"given":"D\u00e9bora","family":"Figueira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Fiuza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreia","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Saraiva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Gon\u00e7alves-Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarida","family":"Borges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2025.11.007_bib0195","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.disamonth.2012.01.009","article-title":"Chronic lymphocytic leukemia","volume":"58","author":"Shanshal","year":"2012","journal-title":"Disease-a-Month"},{"key":"10.1016\/j.repc.2025.11.007_bib0200","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.repc.2025.11.007_bib0205","year":"2024","journal-title":"NCCN clinical practice guidelines in oncology \u2013 chronic lymphocytic leukemia\/small lymphocytic lymphoma version 3.2024"},{"key":"10.1016\/j.repc.2025.11.007_bib0210","first-page":"1","article-title":"Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis","volume":"7","author":"Kreuzberger","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.repc.2025.11.007_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14740\/jh482","article-title":"Efficacy of ibrutinib-based regimen in chronic lymphocytic leukemia: a systematic review","volume":"8","author":"Sardar","year":"2019","journal-title":"J Hematol"},{"key":"10.1016\/j.repc.2025.11.007_bib0220","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1080\/03007995.2020.1784120","article-title":"Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents","volume":"36","author":"Waweru","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.repc.2025.11.007_bib0225","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first-line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.repc.2025.11.007_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms25042208","article-title":"Bruton's tyrosine kinase inhibitors: recent updates","volume":"25","author":"Fares","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.repc.2025.11.007_bib0235","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances","volume":"35","author":"Wen","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.repc.2025.11.007_bib0240","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.repc.2025.11.007_bib0245","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2025.11.007_bib0250","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jha2.638","article-title":"A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States","volume":"4","author":"Mato","year":"2023","journal-title":"EJHaem"},{"key":"10.1016\/j.repc.2025.11.007_bib0255","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/cncr.34787","article-title":"Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: focus on hypertension and cardiovascular toxicity","volume":"129","author":"Gordon","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.repc.2025.11.007_bib0260","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1200\/JCO.21.00693","article-title":"Cardiovascular risk associated with ibrutinib use in chronic lymphocytic leukemia: a population-based cohort study","volume":"39","author":"Abdel-Qadir","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.repc.2025.11.007_bib0265","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","volume":"20","author":"Lipsky","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"10.1016\/j.repc.2025.11.007_bib0270","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood.V128.22.642.642","article-title":"Twice daily dosing with the highly specific BTK inhibitor, Bgb-3111 achieves complete and continuous BTK occupancy in lymph nodes, and is associated with durable responses in patients (pts) with chronic lymphocytic leukemia (CLL)\/small lymphocytic lympho","volume":"128","author":"Tam","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.repc.2025.11.007_bib0275","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2019-125394","article-title":"Efficacy and safety of zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with Del(17p): initial results from arm C of the sequoia (BGB-3111-304) trial","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.repc.2025.11.007_bib0280","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1182\/blood-2019-124213","article-title":"ALPINE: phase 3 trial of zanubrutinib (BGB-3111) vs ibrutinib in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL)","volume":"134","author":"Hillmen","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.repc.2025.11.007_bib0285","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1158\/1078-0432.CCR-19-3504","article-title":"Phase Ib study of tirabrutinib in combination with idelalisib or entospletinib in previously treated chronic lymphocytic leukemia","volume":"26","author":"Danilov","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.repc.2025.11.007_bib0290","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2025.11.007_bib0295","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","article-title":"Ibrutinib treatment for first-line and relapsed\/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib\/II PCYC-1102 study","volume":"26","author":"Byrd","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.repc.2025.11.007_bib0300","series-title":"Morbilidade e Mortalidade Hospitalar \u2013 Portal de dados abertos da administra\u00e7\u00e3o p\u00fablica","year":"2023"},{"key":"10.1016\/j.repc.2025.11.007_bib0305","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.repc.2015.07.004","article-title":"Custo-efetividade dos novos anticoagulantes orais na fibrilha\u00e7\u00e3o auricular em Portugal","volume":"34","author":"Costa","year":"2015","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.repc.2025.11.007_bib0310","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.repc.2020.08.007","article-title":"Atherosclerosis: the cost of illness in Portugal","volume":"40","author":"Costa","year":"2021","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.repc.2025.11.007_bib0315","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.repc.2025.11.007_bib0320","doi-asserted-by":"crossref","first-page":"E387","DOI":"10.1002\/ajh.27110","article-title":"A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"98","author":"Kittai","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.repc.2025.11.007_bib0325","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000801","article-title":"Acalabrutinib versus investigator's choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND trial results","volume":"6","author":"Ghia","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.repc.2025.11.007_bib0330","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e18729","article-title":"Real-world evidence of impact of atrial fibrillation (AF) on clinical and economic outcomes in patients with chronic lymphocytic leukemia (CLL)","volume":"40","author":"Yang","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.repc.2025.11.007_bib0335","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","article-title":"Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people","volume":"383","author":"Rapsomaniki","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.repc.2025.11.007_bib0340","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1182\/bloodadvances.2024013348","article-title":"Cardiovascular toxicity of Bruton tyrosine kinase inhibitors: forget about selectivity but watch the clock","volume":"8","author":"Minotti","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.repc.2025.11.007_bib0345","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jacep.2022.11.034","article-title":"Kinase inhibitors and atrial fibrillation: mechanisms of action and clinical implications","volume":"9","author":"Potter","year":"2023","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.repc.2025.11.007_bib0350","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.repc.2025.11.007_bib0355","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.clinthera.2023.11.014","article-title":"Cardiovascular adverse events associated with second-generation bruton tyrosine kinase inhibitor therapy: a systematic review and meta-analysis","volume":"46","author":"Proskuriakova","year":"2024","journal-title":"Clin Ther"},{"key":"10.1016\/j.repc.2025.11.007_bib0360","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.jval.2023.09.342","article-title":"Real-world comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib","volume":"26","author":"Rogers","year":"2023","journal-title":"Value Heal"},{"key":"10.1016\/j.repc.2025.11.007_bib0365","article-title":"Evaluation of healthcare resource utilization and cost among first-line patients receiving ibrutinib vs acalabrutinib for chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): a commercial claims database analysis","volume":"26","author":"Muluneh","year":"2023","journal-title":"Value Heal"},{"key":"10.1016\/j.repc.2025.11.007_bib0370","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-200345","article-title":"Healthcare resource utilization and costs in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) treated with covalent Btki (cBTKi): real-world impact of cardiovascular adverse events","volume":"144","author":"Obeng-Kusi","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.repc.2025.11.007_bib0375","article-title":"Real-world treatment patterns, adverse events, resource use, and costs among commercially insured, younger patients with chronic lymphocytic leukemia in the USA: a retrospective cohort study","volume":"37","author":"Kabadi","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.repc.2025.11.007_bib0380","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"100","author":"Lipsky","year":"2015","journal-title":"Haematologica"}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255126000296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255126000296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:30:30Z","timestamp":1774614630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0870255126000296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0870255126000296"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2025.11.007","relation":{},"ISSN":["0870-2551"],"issn-type":[{"value":"0870-2551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Costs and consequences of cardiovascular toxicity due to Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2025.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}